Virax Biolabs Group Stock Buy Hold or Sell Recommendation
| VRAX Stock | USD 2.07 0.05 2.48% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Virax Biolabs Group is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Virax Biolabs Group given historical horizon and risk tolerance towards Virax Biolabs. When Macroaxis issues a 'buy' or 'sell' recommendation for Virax Biolabs Group, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Virax Biolabs Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Virax and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Virax |
Execute Virax Biolabs Buy or Sell Advice
The Virax recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Virax Biolabs Group. Macroaxis does not own or have any residual interests in Virax Biolabs Group or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Virax Biolabs' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Sell | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Virax Biolabs Trading Alerts and Improvement Suggestions
| Virax Biolabs Group generated a negative expected return over the last 90 days | |
| Virax Biolabs Group has high historical volatility and very poor performance | |
| Virax Biolabs Group currently holds 224.3 K in liabilities. Virax Biolabs Group has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Virax Biolabs' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 156.42 K. Net Loss for the year was (6.74 M) with loss before overhead, payroll, taxes, and interest of (1.36 K). | |
| Virax Biolabs Group currently holds about 21.76 K in cash with (6.25 M) of positive cash flow from operations. | |
| Latest headline from simplywall.st: Virax Biolabs Group First Half 2025 Earnings US0.89 loss per share |
Virax Biolabs Returns Distribution Density
The distribution of Virax Biolabs' historical returns is an attempt to chart the uncertainty of Virax Biolabs' future price movements. The chart of the probability distribution of Virax Biolabs daily returns describes the distribution of returns around its average expected value. We use Virax Biolabs Group price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Virax Biolabs returns is essential to provide solid investment advice for Virax Biolabs.
| Mean Return | -0.93 | Value At Risk | -12.9 | Potential Upside | 9.65 | Standard Deviation | 9.12 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Virax Biolabs historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Virax Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Virax Biolabs, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Virax Biolabs Group back and forth among themselves.
| Shares | Renaissance Technologies Corp | 2024-09-30 | 145.4 K | Virtu Financial Llc | 2024-06-30 | 28.1 K | Hrt Financial Llc | 2024-06-30 | 25.7 K | Ubs Group Ag | 2024-06-30 | 5.6 K | Qube Research & Technologies | 2024-06-30 | 300 | Headlands Technologies Llc | 2024-09-30 | 185 | Wells Fargo & Co | 2024-06-30 | 100.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
Virax Biolabs Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Virax Biolabs or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Virax Biolabs' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Virax stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.89 | |
β | Beta against Dow Jones | -0.43 | |
σ | Overall volatility | 9.27 | |
Ir | Information ratio | -0.12 |
Virax Biolabs Volatility Alert
Virax Biolabs Group is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Virax Biolabs' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Virax Biolabs' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Virax Biolabs Fundamentals Vs Peers
Comparing Virax Biolabs' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Virax Biolabs' direct or indirect competition across all of the common fundamentals between Virax Biolabs and the related equities. This way, we can detect undervalued stocks with similar characteristics as Virax Biolabs or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Virax Biolabs' fundamental indicators could also be used in its relative valuation, which is a method of valuing Virax Biolabs by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Virax Biolabs to competition |
| Fundamentals | Virax Biolabs | Peer Average |
| Return On Equity | -0.96 | -0.31 |
| Return On Asset | -0.5 | -0.14 |
| Operating Margin | (42.54) % | (5.51) % |
| Current Valuation | 2.08 M | 16.62 B |
| Shares Outstanding | 4.34 M | 571.82 M |
| Shares Owned By Insiders | 7.06 % | 10.09 % |
| Shares Owned By Institutions | 5.37 % | 39.21 % |
| Number Of Shares Shorted | 284.03 K | 4.71 M |
| Price To Book | 1.04 X | 9.51 X |
| Price To Sales | 57.46 X | 11.42 X |
| Revenue | 156.42 K | 9.43 B |
| Gross Profit | (1.36 K) | 27.38 B |
| EBITDA | (6.61 M) | 3.9 B |
| Net Income | (6.74 M) | 570.98 M |
| Cash And Equivalents | 21.76 K | 2.7 B |
| Total Debt | 224.3 K | 5.32 B |
| Current Ratio | 0.04 X | 2.16 X |
| Book Value Per Share | 2.08 X | 1.93 K |
| Cash Flow From Operations | (6.25 M) | 971.22 M |
| Short Ratio | 0.11 X | 4.00 X |
| Earnings Per Share | (2.61) X | 3.12 X |
| Target Price | 20.0 | |
| Number Of Employees | 17 | 18.84 K |
| Beta | 1.93 | -0.15 |
| Market Capitalization | 8.99 M | 19.03 B |
| Total Asset | 5.48 M | 29.47 B |
| Retained Earnings | (18.53 M) | 9.33 B |
| Working Capital | 4.21 M | 1.48 B |
| Net Asset | 5.48 M |
Virax Biolabs Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Virax . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Virax Biolabs Buy or Sell Advice
When is the right time to buy or sell Virax Biolabs Group? Buying financial instruments such as Virax Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Virax Biolabs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Munis Funds Thematic Idea Now
Munis Funds
Funds or Etfs that invest in fixed income securities issued by states, cities, and towns as well as other public entities. The Munis Funds theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Munis Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.